No. As of September 2026, Whitehawk Therapeutics Inc (WHWK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.07% / 30% · (Cash+Inv) / Mkt Cap (36m) 53.4% / 30% · Interest income / Revenue 173700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.07% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 53.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 173700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.07% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 53.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 173700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.03% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 97.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 173700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.13% / 33.33% · (Cash+ST Inv) / Total Assets 97.7% / 33.33% · (Cash+Recv) / Total Assets 97.7% / 33.33% · Interest income / Revenue 173700000.0% / 5% | Fail |
No. As of September 2026, Whitehawk Therapeutics Inc (WHWK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Whitehawk Therapeutics Inc is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 173700000.0% of each dividend: Whitehawk Therapeutics Inc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Whitehawk Therapeutics Inc (NASDAQ: WHWK) is a Healthcare company (Biotechnology) with a market capitalization of $182M. The Maz Rating grades it against the other companies in its sector.
Whitehawk Therapeutics Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $3.08, Whitehawk Therapeutics Inc trades at 1.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -55.7%, return on invested capital of -54.8% and a free cash flow yield of -40.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.47. Over the past 52 weeks the share price ranged from $1.97 to $5.50, with a beta of 0.81.
Whitehawk Therapeutics Inc does not currently pay a dividend.
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.